Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Earnings Presentation for the Quarter ended 30th June, ....

Date: 03.08.2026 BSE Limited Stock ID: TLL 14th Floor, P. J. Towers, Scrip Code: 543616 Dalal Street, Fort, Mumbai – 400001. Sub: Earnings Presentation-Q1 & FY27. Pursuant to Regulation 30 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, please find enclosed herewith Earnings Presentation for the Quarter ended 30th June, 2026. (Q1 & FY27). Kindly take the above on record. Thanking You, Yours Faithfully For TRIDENT LIFELINE LIMITED SHRAVAN H PATEL MANAGING DIRECTOR DIN: 08629141 Encl: As Above Registered Office: 2004, 2nd Floor, North Extension, Falsawadi, Ring Road, Surat-395003, Gujarat, INDIA. Tel : +91 261 2451274, 2451284 Email : info@tridentlifeline.com Web : www.tridentlifeline.com Factory Address: Plot No. 4240, Road No. 42, Sachin GIDC, Surat, Gujarat - 394230, India. Investor Presentation Trident Lifeline Limited (TLL) August 2026 Inside this presentation 04 06 16 25 27 Earnings About Our right Investment Financial update us to win rationale overview Performance update and management commentary 04 Earnings update 04 | EARNINGS UPDATES Performance update and management commentary Management commentary Over the past decade, our journey has been defined by disciplined investment. Our dedication toward securing approvals, building manufacturing infrastructure, creating execution capabilities, and establishing a strong platform for long-term growth has begun yielding significant results over the last two to three years. As more projects became operational and execution gathered momentum, we successfully translated years of capital deployment into revenue-generating assets and a stronger operating platform. Today, it gives me immense pleasure to inform our stakeholders that we have reached the Rs 100 crore plus milestone on both a standalone and consolidated basis. Supported by ongoing operational improvements and a healthy pipeline across both our standalone business and subsidiaries, we are entering our next phase of growth. In parallel, we have made strategic investments in new businesses to diversify our growth platform. As these ventures move beyond the incubation phase, we expect them to contribute meaningfully to our consolidated financial performance. Backed by these structural growth drivers, we remain confident in our long-term outlook and aspire to triple our consolidated business over the next three years through disciplined execution and sustained operational excellence. Our objective is not only to grow revenues but to build a diversified healthcare ecosystem that can create sustainable value for customers, partners, and shareholders over the long term - Hardik Desai, Chairman Company overview 06 Our business model 08 About us Our journey 09 Our subsidiaries 10 06 | ABOUT US: COMPANY OVERVIEW Creating long term value through scalable expansion Revenue from operations Operating profit (EBITDA) Profit after tax CAGR: 56% CAGR: 79% CAGR: 49% 129.0 28.1 19.3 87.0 14.9 10.5 44.6 8.2 6.0 5.9 31.7 21.8 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 FY22 FY23 FY24 FY25 FY26 Demonstrated exceptional growth momentum with sustained improvement in scale and profitability 07 | ABOUT US: COMPANY OVERVIEW Building a global healthcare platform The integrated trident ecosystem Trident at a glance Building a diversified manufacturing platform across formulations and medical devices ▪ Established in 2014 as an export-focused pharmaceutical company, building a scalable global healthcare platform Oral solids Liquids ▪ Diversified portfolio spanning pharmaceuticals, nutraceuticals, (Tablets / Capsules) (Syrups, Solutions) herbals, injectables, personal care, and medical devices ▪ Hybrid manufacturing model combining strategic partnerships with integrated manufacturing capabilities to enhance scalability Dry powder Ointments and sachets and topicals and supply reliability Platform ▪ Integrated WHO-GMP compliant manufacturing platform with scalable capabilities across oral solids, injectables, liquids, and Injectables Medical devices medical devices (Vials, Ampoules) and surgical 5 10+ 80 crs. 40% 4 129.0 crs. 21.8% Business Years of Intrinsic value Capacity Manufacturing FY26 FY26 verticals experience of registrations utilization facilities revenue EBITDA margin We partner with distributors for market access while serving as their dedicated manufacturing and supply partner 08 | ABOUT US: OUR BUSINESS MODEL An integrated model creating value across the pharmaceutical value chain N Our operational excellence and H strategic enablers create a Procurement Manufacturing Exports self-reinforcing cycle of growth A Consolidated manufacturing L ▪ Trusted indigenous ▪ WHO-GMP compliant ▪ Strong presence across capacity (in million) / month1 N sourcing ensuring manufacturing with regulated and emerging I quality and cost scalable operations markets T Tablets 120 efficiency Capsules 120 E Dry powder bottles 3 U Regulatory and Sales and Distribution and A registration marketing patient reach N Ointments 3 T ▪ Country-specific ▪ Distributor-led marketing ▪ Robust distribution E regulatory approvals model with dedicated network enhancing C enabling market access manufacturing support product availability and Liquid bottles 3 R and product launches market penetration B Injectables 10 Registration → Market Access → Sales and Distribution → Integrated Demand → Quality Delivery → Cash Generation → Long-term Investment 1: Capacity utilization is based on two-shift operations 09 | ABOUT US: OUR JOURNEY Building a global pharmaceutical platform 2015 - 2016 2021 - 2022 2024 2025 2026 Company formation Market expansion Strategic growth Operational scale Building future pipeline ▪ Beginning of ▪ Plant approvals ▪ Commercial operation ▪ Commercial operation of ▪ Commercial implementation of operations ▪ Export to Latin and of TNS TLL Liquid Facility TLL Parenterals Injectible facility ▪ Strategic alliance CIS countries ▪ Incorporated TLL ▪ Incorporated TLL ▪ Planning underway for TLL Cefa for manufacturing ▪ Listing on BSE SME Wellness Limited1 Parenterals Limited Facility ▪ Export to Africa ▪ Incorporated TNS ▪ Presence in 30 countries ▪ Acquired Trident Mediquip ▪ Planning underway for launch of Pharma Private Limited nutraceutical product range Limited ▪ Launched cosmetic range ▪ Acquisition of 50,000 sq. meters under the brand name of land "YES" ▪ Presence in 46 countries ▪ Strategic alliance with NIPER – Ahmedabad ▪ Presence in 43 countries Driving Growth Building Strong Foundation Gaining Momentum 129.0 44.6 FY15 FY16 FY17 FY18 FY19 FY20 FY21 FY22 FY23 FY24 FY25 FY26 1: Erstwhile TLL Herbal Limited 10 | ABOUT US: OUR SUBSIDIARY TNS Pharma Private Limited Operational metrics ▪ Manufactures high-quality tablets, capsules and dry powder Peak revenue suspension 40 crs. ▪ Operates under WHO-GMP standards with advanced infrastructure ▪ Strategic Importance: Driving capacity expansion, margin Peak utilization enhancement, operational integration, and sustainable long-term growth through a core manufacturing asset Steady state EBITDA margin OWNERSHIP BUSINESS 51% Pharmaceuticals and medicinal products Trident Lifeline Limited Steady state PAT margin 120 Mn 120 Mn 3 Mn PRODUCTION CAPACITY1 FY26 revenue Tablets Capsules Dry Powder (PER MONTH) Bottles 6 crs. 1: Production capacity is based on two-shift operations 11 | ABOUT US: OUR SUBSIDIARY Trident Mediquip Limited Operational metrics Peak revenue ▪ Manufacturing in the medical devices segment, with products 70 crs. such as Double Safety IV Cannulas and Air Block Mechanism Infusion (IFG) Sets ▪ Offers a diversified portfolio of medical devices catering to Peak utilization evolving healthcare needs Lorem ipsum dolor sit amet Steady state EBITDA margin OWNERSHIP BUSINESS 60% Medical Devices Trident Lifeline Limited Steady state PAT margin 6 Mn 3 Mn 1.2 Mn 0.2Mn PRODUCTION CAPACITY1 FY26 revenue Reg IV Cannula Reg IFG Set Saf IV Cannula Saf IFG Set (PER MONTH) 27 crs. Lorem ipsum dolor sit amet [Showing first 8,000 characters — download PDF for full document]